{"id":14758,"date":"2023-11-13T04:24:19","date_gmt":"2023-11-13T04:24:19","guid":{"rendered":"https:\/\/galenica.cl\/english\/?post_type=product&p=14758"},"modified":"2023-12-07T15:28:10","modified_gmt":"2023-12-07T15:28:10","slug":"teg6s-hemostasis-analyzer","status":"publish","type":"product","link":"https:\/\/galenica.cl\/english\/product\/teg6s-hemostasis-analyzer\/","title":{"rendered":"TEG\u00ae6s Hemostasis Analyzer"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n

\nThe TEG 6s system, in combination with clinical information, provides rapid, comprehensive and accurate identification of an individual\u2019s hemostasis condition. Featuring an innovative, all-in-one cartridge, the TEG 6s delivers the same quality test results without the complicated test preparation process. TEG 6s allows clinicians to drive personalized, clinically and economically sound treatment and monitoring decisions with confidence.<\/p>\n

Features:
\nResonance Technology<\/p>\n

The TEG\u00ae 6s system measures the same physical properties as the TEG 5000 Thrombelastograph\u00ae system, with assessment of clot viscoelasticity throughout the coagulation process.
\nNew to the TEG system technology is the measurement of clot viscoelasticity using a resonance method. To measure the clot strength with the resonance method, the sample is exposed to a fixed vibration frequency. With LED illumination, a detector measures up\/down motion of the blood meniscus. The frequency leading to resonance is identified and then converted to the TEG system readout. Stronger clots have higher resonant frequencies and higher TEG readouts.
\nTest Cartridges<\/p>\n

TEG\u00ae 6s assays are performed in microfluidic cartridges designed for simultaneous performance of multiple TEG assays. Preparing the blood sample for the TEG 6s system analysis is very simple. There is no need for controlled pipetting or prior manipulation of reagents. The only requirement is to transfer a small, unmetered amount of blood to the loaded cartridge from a sample tube with citrate or heparin.The TEG 6s system, in combination with clinical information, provides rapid, comprehensive and accurate identification of an individual\u2019s hemostasis condition. Featuring an innovative, all-in-one cartridge, the TEG 6s delivers the same quality test results without the complicated test preparation process. TEG 6s allows clinicians to drive personalized, clinically and economically sound treatment and monitoring decisions with confidence.<\/p>\n

Features:
\nResonance Technology<\/p>\n

The TEG\u00ae 6s system measures the same physical properties as the TEG 5000 Thrombelastograph\u00ae system, with assessment of clot viscoelasticity throughout the coagulation process.
\nNew to the TEG system technology is the measurement of clot viscoelasticity using a resonance method. To measure the clot strength with the resonance method, the sample is exposed to a fixed vibration frequency. With LED illumination, a detector measures up\/down motion of the blood meniscus. The frequency leading to resonance is identified and then converted to the TEG system readout. Stronger clots have higher resonant frequencies and higher TEG readouts.
\nTest Cartridges<\/p>\n

TEG\u00ae 6s assays are performed in microfluidic cartridges designed for simultaneous performance of multiple TEG assays. Preparing the blood sample for the TEG 6s system analysis is very simple. There is no need for controlled pipetting or prior manipulation of reagents. The only requirement is to transfer a small, unmetered amount of blood to the loaded cartridge from a sample tube with citrate or heparin.<\/p>\n<\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"

The TEG 6s system, in combination with clinical information, provides rapid, comprehensive and accurate identification of an individual\u2019s hemostasis condition. Featuring an innovative, all-in-one cartridge, the TEG 6s delivers the same quality test results without the complicated test preparation process. TEG 6s allows clinicians to drive personalized, clinically and economically sound treatment and monitoring decisions with confidence.<\/p>\n